SCHEMBL18189596

SCHEMBL18189596

O=C1Cc2cc(-c3c(Cl)cncc3Cl)ccc2N1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PDE3B Q13370 1/20 0.61
▸ PDE3A Q14432 1/20 0.61
▸ GRIA1 P42261 8/20 0.61
▸ CACNG8 Q8WXS5 6/20 0.61
▸ CYP1A2 P05177 1/20 0.58
▸ CYP11B1 P15538 1/20 0.58
▸ CYP11B2 P19099 1/20 0.58
▸ PGR P06401 3/20 0.57
▸ AHR P35869 1/20 0.55
▸ BCL6 P41182 1/20 0.53
▸ BMPR1B O00238 1/20 0.51
▸ BMPR1A P36894 1/20 0.51
▸ TGFBR1 P36897 1/20 0.51
▸ ACVRL1 P37023 1/20 0.51
▸ ACVR1 Q04771 1/20 0.51
▸ PDE4A P27815 1/20 0.47
▸ PDE4B Q07343 1/20 0.47
▸ PDE4C Q08493 1/20 0.47
▸ PDE4D Q08499 1/20 0.47
▸ CRBN Q96SW2 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18189570 0.85 GRIA1 (0.73) PDE3BPDE3AGRIA1CACNG8CYP1A2
SCHEMBL18189519 0.81 GRIA1 (0.62) PDE3BPDE3AGRIA1CACNG8CYP1A2
SCHEMBL18189648 0.79 GRIA1 (0.56) PDE3BPDE3AGRIA1CACNG8CYP1A2
SCHEMBL1900155 0.78 AHR (0.77) PDE3BPDE3AGRIA1CACNG8CYP1A2
SCHEMBL18189600 0.78 GRIA1 (0.57) PDE3BPDE3AGRIA1CACNG8CYP1A2
SCHEMBL18189493 0.78 GRIA1 (0.55) PDE3BPDE3AGRIA1CACNG8CYP1A2
SCHEMBL22202070 0.77 PDE3B (0.71) PDE3BPDE3AGRIA1CACNG8CYP1A2
SCHEMBL18189478 0.77 PDE3B (0.65) PDE3BPDE3AGRIA1CACNG8CYP1A2
SCHEMBL18189652 0.77 CYP11B1 (0.68) PDE3BPDE3AGRIA1CACNG8CYP1A2
SCHEMBL23143482 0.76 PDE3B (1.00) PDE3BPDE3AGRIA1CACNG8CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107750250-B Indolone compounds and their use as AMPA receptor modulators 詹森药业有限公司 2021-09-07 — — CN claimed
US-10604484-B2 Indolone compounds and their use as AMPA receptor modulators JANSSEN PHARMACEUTICA NV (BE) 2020-03-31 — — US claimed
EP-3288935-B1 INDOLONE COMPOUNDS AND THEIR USE AS AMPA RECEPTOR MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2019-10-30 — — EP claimed
US-20180118683-A1 INDOLONE COMPOUNDS AND THEIR USE AS AMPA RECEPTOR MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2018-05-03 — — US claimed
EP-3288935-A1 INDOLONE COMPOUNDS AND THEIR USE AS AMPA RECEPTOR MODULATORS Janssen Pharmaceutica NV (BE) 2018-03-07 — — EP claimed
WO-2016176463-A1 INDOLONE COMPOUNDS AND THEIR USE AS AMPA RECEPTOR MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2016-11-03 — — WO claimed
CN-107750250-B Indolone compounds and their use as AMPA receptor modulators 詹森药业有限公司 2021-09-07 — — CN disclosed
US-10604484-B2 Indolone compounds and their use as AMPA receptor modulators JANSSEN PHARMACEUTICA NV (BE) 2020-03-31 — — US disclosed
US-10604484-B2 Indolone compounds and their use as AMPA receptor modulators JANSSEN PHARMACEUTICA NV (BE) 2020-03-31 — — US disclosed
EP-3288935-B1 INDOLONE COMPOUNDS AND THEIR USE AS AMPA RECEPTOR MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2019-10-30 — — EP disclosed
US-20180118683-A1 INDOLONE COMPOUNDS AND THEIR USE AS AMPA RECEPTOR MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2018-05-03 — — US disclosed
US-20180118683-A1 INDOLONE COMPOUNDS AND THEIR USE AS AMPA RECEPTOR MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2018-05-03 — — US disclosed
US-20180118683-A1 INDOLONE COMPOUNDS AND THEIR USE AS AMPA RECEPTOR MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2018-05-03 — — US disclosed
EP-3288935-A1 INDOLONE COMPOUNDS AND THEIR USE AS AMPA RECEPTOR MODULATORS Janssen Pharmaceutica NV (BE) 2018-03-07 — — EP disclosed
WO-2016176463-A1 INDOLONE COMPOUNDS AND THEIR USE AS AMPA RECEPTOR MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2016-11-03 — — WO disclosed
WO-2016176463-A1 INDOLONE COMPOUNDS AND THEIR USE AS AMPA RECEPTOR MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2016-11-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10604484-B2 Indolone compounds and their use as AMPA receptor modulators GRIN3A, GRIN1, GRIN2B PDE3B 1272/4885PDE3A 1131/4885GRIA1 23/4885
US-20180118683-A1 INDOLONE COMPOUNDS AND THEIR USE AS AMPA RECEPTOR MODULATORS GRIN3A, GRIN1, GRIN2B PDE3B 1272/4885PDE3A 1131/4885GRIA1 23/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback